News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
381,558 Results
Type
Article (33296)
Company Profile (64)
Press Release (348198)
Section
Business (102449)
Career Advice (2556)
Deals (18520)
Drug Delivery (92)
Drug Development (50157)
Employer Resources (152)
FDA (9427)
Job Trends (9586)
News (184199)
Policy (19442)
Tag
Academia (2098)
Alliances (25630)
Alzheimer's disease (933)
Approvals (9414)
Artificial intelligence (130)
Bankruptcy (131)
Best Places to Work (7866)
Breast cancer (174)
Cancer (1182)
Cardiovascular disease (98)
Career advice (2147)
CAR-T (100)
Cell therapy (247)
Clinical research (40254)
Collaboration (387)
Compensation (221)
COVID-19 (2086)
Data (1146)
Diabetes (155)
Diagnostics (3727)
Earnings (47519)
Employer resources (133)
Events (57998)
Executive appointments (254)
FDA (9990)
Funding (318)
Gene therapy (207)
GLP-1 (475)
Government (3347)
Healthcare (12200)
Infectious disease (2164)
Interviews (461)
IPO (9272)
Job creations (2077)
Job search strategy (1775)
Layoffs (334)
Legal (4225)
Lung cancer (188)
Lymphoma (92)
Manufacturing (155)
Medical device (7575)
Medtech (7576)
Mergers & acquisitions (9497)
Metabolic disorders (423)
Neuroscience (1237)
NextGen: Class of 2025 (4329)
Non-profit (3354)
Northern California (1207)
Obesity (228)
Opinion (217)
Parkinson's disease (87)
Patents (85)
People (21934)
Phase I (11516)
Phase II (17507)
Phase III (14884)
Pipeline (484)
Postmarket research (1694)
Preclinical (4797)
Radiopharmaceuticals (122)
Rare diseases (247)
Real estate (3168)
Regulatory (13079)
Research institute (1737)
Resumes & cover letters (429)
Southern California (1077)
Startups (1943)
United States (10759)
Vaccines (496)
Weight loss (173)
Date
Last 7 days (374)
Last 30 days (1536)
Last 365 days (20823)
2025 (2694)
2024 (21124)
2023 (23711)
2022 (30573)
2021 (34411)
2020 (33020)
2019 (29322)
2018 (22556)
2017 (18893)
2016 (18895)
2015 (21432)
2014 (15556)
2013 (12830)
2012 (13513)
2011 (14252)
2010 (12202)
Location
Africa (643)
Arizona (108)
Asia (23020)
Australia (3913)
California (2755)
Canada (1085)
China (233)
Colorado (127)
Connecticut (143)
Europe (52702)
Florida (422)
Georgia (102)
Illinois (295)
Indiana (172)
Japan (88)
Maryland (437)
Massachusetts (2003)
Michigan (102)
Minnesota (165)
New Jersey (875)
New York (843)
North Carolina (521)
Northern California (1207)
Ohio (85)
Pennsylvania (642)
South America (906)
Southern California (1077)
Texas (385)
Utah (93)
Washington State (229)
381,558 Results for "one drop".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Allakos Will Axe 75% of Workforce, Drop Hives Candidate
Following disappointing clinical trial results for AK006, Allakos will cut its workforce down to under 20 employees as it explores strategic alternatives.
January 27, 2025
·
1 min read
·
Angela Gabriel
Business
Takeda Drops Epilepsy Drug, Names New CEO Amid Q3 Earnings
Analysts were unfazed by the news that Takeda will cease development of soticlestat after Phase III failures, while responding positively to the announcement that Julie Kim will take the helm of the Japanese giant in 2026.
January 30, 2025
·
1 min read
·
Dan Samorodnitsky
Weight loss
BioAge Drops Lead Obesity Asset Months After IPO
It’s been a rocky few months for BioAge Labs, which shuttered a Phase II trial of its lead candidate azelaprag Tuesday after the molecule caused liver-based side effects.
January 28, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
AgelessRx Expands Offerings to Include Oral GLP-1 Drops to Advance Metabolic Health and Longevity Science
February 5, 2025
·
4 min read
BIOSECURE Act
WuXi AppTec Hit With Slight Drop in US Revenue as Threat of BIOSECURE Act Looms
With the BIOSECURE Act likely to be voted on in Congress this year, WuXi AppTec’s U.S. revenue dropped 1.2% in the first half of 2024 while the Chinese company increased its lobbying efforts.
July 29, 2024
·
2 min read
·
Tyler Patchen
Deals
Lilly Drops Up to $2.5B for Scorpion’s PI3K-inhibitor Molecule
The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.
January 13, 2025
·
2 min read
·
Dan Samorodnitsky
Pipeline
Neurogene Drops Batten Gene Therapy Program
After failing to receive the RMAT designation from the FDA for its early-stage Batten disease gene therapy, Neurogene tells investors that it’s evaluating options for the program.
November 19, 2024
·
2 min read
·
Kate Goodwin
Business
Analysts Tell Moderna Investors to Hold After 2024’s Steep Drop
The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year of consistent share value decline, analysts remain skeptical.
December 17, 2024
·
3 min read
·
Kate Goodwin
Policy
GSK Appeals Delaware Court’s Decision in Zantac Cases as Plaintiff Drops Lawsuit
On Monday, GSK reported that a plaintiff voluntarily dropped her Zantac case against the company and that it is in the process of appealing a Delaware State Court’s decision to admit expert testimony in other cases.
June 11, 2024
·
2 min read
·
Tristan Manalac
Business
5 Reasons Biogen’s Shares Have Dropped 36% in 2024
A slow launch for Alzheimer’s medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a few of the factors that have sent Biogen’s shares down this year.
November 13, 2024
·
7 min read
·
Annalee Armstrong
1 of 38,156
Next
